Anidulafungin treatment of candidal central nervous system infection in a murine model.
We established a murine model of Candida albicans central nervous system (CNS) infection and evaluated the efficacy of anidulafungin. Ten milligrams/kg/day anidulafungin, amphotericin B, or voriconazole significantly reduced mortality and fungal burden in brain tissue, although amphotericin B and 10 mg/kg/day anidulafungin reduced fungal burden in brain tissue to a greater extent than did voriconazole. This suggests a potential role for anidulafungin in the treatment of candidal CNS infection.
Kang
Cheol-In
CI
Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Rouse
Mark S
MS
Mandrekar
Jayawant N
JN
Steckelberg
James M
JM
Patel
Robin
R
D000666:Amphotericin B / Q000097:blood / Q000627:therapeutic use; D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000097:blood / Q000627:therapeutic use*; D002176:Candida albicans / Q000502:physiology; D002177:Candidiasis / Q000188:drug therapy* / Q000401:mortality; D002494:Central Nervous System Infections / Q000188:drug therapy* / Q000382:microbiology* / Q000401:mortality; D004195:Disease Models, Animal; D054714:Echinocandins / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D051379:Mice; D011743:Pyrimidines / Q000097:blood / Q000627:therapeutic use; D014230:Triazoles / Q000097:blood / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D000077612:Anidulafungin; D065819:Voriconazole